SINT

Company Overview — What Does Sintx Technologies, Inc. Do?

Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. Sintx Technologies, Inc. (SINT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO B. Sonny Bal and employs approximately 40 people, headquartered in Salt Lake City, Utah. With a market capitalization of $10M, SINT is one of the notable companies in the Healthcare sector.

Sintx Technologies, Inc. (SINT) Stock Rating — Avoid (April 2026)

As of April 2026, Sintx Technologies, Inc. receives a Avoid rating with a composite score of 22.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.SINT ranks #4,176 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Sintx Technologies, Inc. ranks #743 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SINT Stock Price and 52-Week Range

Sintx Technologies, Inc. (SINT) currently trades at $2.64. The stock lost $0.05 (1.9%) in the most recent trading session. The 52-week high for SINT is $6.78, which means the stock is currently trading -61.1% from its annual peak. The 52-week low is $1.71, putting the stock 54.4% above its annual trough. Recent trading volume was 13K shares, suggesting relatively thin trading activity.

Is SINT Overvalued or Undervalued? — Valuation Analysis

Sintx Technologies, Inc. (SINT) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.74x, versus the sector average of 2.75x. The price-to-sales ratio is 7.18x, compared to 1.66x for the average Healthcare stock.

At current multiples, Sintx Technologies, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Sintx Technologies, Inc. Profitability — ROE, Margins, and Quality Score

Sintx Technologies, Inc. (SINT) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -491.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -151.4% versus the sector average of -33.1%.

On a margin basis, Sintx Technologies, Inc. reports gross margins of 47.4%, compared to 71.5% for the sector. The operating margin is -1206.4% (sector: -66.1%). Net profit margin stands at -1159.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -75.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SINT Debt, Balance Sheet, and Financial Health

Sintx Technologies, Inc. has a debt-to-equity ratio of 225.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.51x, suggesting adequate working capital coverage. Total debt on the balance sheet is $59,000. Cash and equivalents stand at $6M.

SINT has a beta of 1.62, meaning it is more volatile than the broader market — a $10,000 investment in SINT would be expected to move 61.5% more than the S&P 500 on any given day. The stability factor score for Sintx Technologies, Inc. is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Sintx Technologies, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Sintx Technologies, Inc. reported revenue of $2M and earnings per share (EPS) of $-6.16. Net income for the quarter was $-14M. Gross margin was 47.4%. Operating income came in at $-15M.

In FY 2025, Sintx Technologies, Inc. reported revenue of $1M and earnings per share (EPS) of $-6.16. Net income for the quarter was $-10M. Gross margin was 45.3%. Revenue grew -64.7% year-over-year compared to FY 2024. Operating income came in at $-11M.

In Q3 2025, Sintx Technologies, Inc. reported revenue of $208,000 and earnings per share (EPS) of $-3.46. Net income for the quarter was $-4M. Gross margin was 44.7%. Revenue grew -74.0% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, Sintx Technologies, Inc. reported revenue of $151,000 and earnings per share (EPS) of $-0.91. Net income for the quarter was $-2M. Gross margin was 37.8%. Revenue grew -82.4% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, Sintx Technologies, Inc. has demonstrated a growth trajectory, with revenue expanding from $859,000 to $2M. Investors analyzing SINT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SINT Dividend Yield and Income Analysis

Sintx Technologies, Inc. (SINT) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SINT Momentum and Technical Analysis Profile

Sintx Technologies, Inc. (SINT) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

SINT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Sintx Technologies, Inc. (SINT) ranks #743 out of 838 stocks based on the Blank Capital composite score. This places SINT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SINT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SINT vs S&P 500 (SPY) comparison to assess how Sintx Technologies, Inc. stacks up against the broader market across all factor dimensions.

SINT Next Earnings Date

No upcoming earnings date has been announced for Sintx Technologies, Inc. (SINT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SINT? — Investment Thesis Summary

The quantitative profile for Sintx Technologies, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 27/100, a headwind for near-term performance. High volatility (stability score 24/100) increases portfolio risk.

In summary, Sintx Technologies, Inc. (SINT) earns a Avoid rating with a composite score of 22.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SINT stock.

Related Resources for SINT Investors

Explore more research and tools: SINT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SINT head-to-head with peers: SINT vs AZN, SINT vs SLGL, SINT vs VMD.